#ASCOGuidelines
LightNews LightNews
ascocancer.bsky.social
ASCO Guideline Update: Therapy for Stage IV NSCLC w/ Driver Alterations

For first-line EGFR exon 20 insertions, clinicians should offer sunvozertinib monotherapy or platinum doublet chemotherapy plus amivantamab.

Read the updated guideline: https://bit.ly/46JViOM
#ASCOGuidelines
September 30, 2026 at 8:15 PM
beverlymoy.bsky.social
@ascocancer.bsky.social #ASCOGuidelines out today "Systemic Therapy for Stage I-III Anal Carcinoma" with guidance about radiosensitization, dose/scheduling options, and much more. @vanmorrismd.bsky.social @cathyengmd.bsky.social Read at society.asco.org/practice-pat...
Gastrointestinal Cancer
Gastrointestinal Cancer
society.asco.org
December 16, 2024 at 11:48 PM
brittanyeharvey.bsky.social
Protocol for future ASCO guideline on patient-reported outcomes available for comment through Wednesday, April 9 @ascocancer.bsky.social #ASCOguidelines #OncSky #MedSky app.smartsheet.com/b/form/ecf22...
Smartsheet Forms
app.smartsheet.com
March 28, 2025 at 8:05 PM
brittanyeharvey.bsky.social
Dr. Evan Yu from @fredhutch.bsky.social discusses which patients with metastatic prostate cancer should receive germline & somatic testing with NGS technologies, what samples are preferred & therapeutic & prognostic impacts of testing on the #ASCOguidelines podcast podcasts.apple.com/us/podcast/g...
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer Guideline
Podcast Episode · ASCO Guidelines · 01/09/2025 · 16m
podcasts.apple.com
January 9, 2025 at 9:36 PM
brittanyeharvey.bsky.social
New rapid recommendation update on systemic therapy for small-cell lung cancer from ASCO just published: ascopubs.org/doi/full/10.... #ASCOguidelines #MedSky #OncSky #LCSM
Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update: 2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong) 5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional) 4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong) 4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong) Kalemkerian et al J Clin Oncol 2024 asco.org/thoracic-cancer-guidelines
November 20, 2024 at 9:39 PM
brittanyeharvey.bsky.social
I spoke with Clara Park @ Brigham & Women's & Mylin Torres from @winshipatemory.bsky.social about this latest SLNB guideline update. We discuss the recommendations, importance of shared decision-making and other ongoing & future de-escalation trials #ASCOguidelines podcasts.apple.com/us/podcast/s...
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Guideline Update
Podcast Episode · ASCO Guidelines · 04/10/2025 · 21m
podcasts.apple.com
April 11, 2025 at 12:31 PM
brittanyeharvey.bsky.social
Protocol for the @ascocancer.bsky.social guideline update on management of immune-related adverse effects available for open comment through March 19 #ASCOguidelines #irAEs #MedSky #OncSky #SuppOnc app.smartsheet.com/b/form/e3689...
Smartsheet Forms
app.smartsheet.com
March 5, 2025 at 5:31 PM
brittanyeharvey.bsky.social
New guideline just out from ASCO on systemic therapy for stage I-III anal squamous cell carcinoma #ASCOguidelines #MedSky #OncSky ascopubs.org/doi/full/10....
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...
ascopubs.org
December 17, 2024 at 3:16 PM
brittanyeharvey.bsky.social
New Treatment of Pleural Mesothelioma Guideline Update just released from @ascocancer.bsky.social! Includes recommendations on diagnosis & staging, surgery, immunotherapy, chemotherapy, radiation therapy, pathology & germline testing #ASCOguidelines #medsky #oncsky ascopubs.org/doi/full/10....
ASCO Guidelines: Treatment of Pleural Mesothelioma Guideline update including recommendations on: Diagnosis and Staging, Surgery, Immunotherapy, Chemotherapy, Radiation Therapy, Pathology, Germline Testing Kindler et al J Clin Oncol 2025 asco.org/thoracic-cancer-guidelines
January 8, 2025 at 9:17 PM
brittanyeharvey.bsky.social
Latest update to the ASCO stage IV NSCLC living guidelines published today! This update focuses on first- and second-line options for patients with an EGFR exon 19 deletion or exon 21 L858R substitution #ASCOguidelines #MedSky #OncSky #LCSM ascopubs.org/doi/full/10....
Visual Abstract for the Therapy for Stage IV NSCLC with Driving Alterations Living Guideline. Living Guideline Updated Recommendations EGFR Exon 19 Deletion, Exon 21 L858R Substitution First-Line Treatment Options Update. 1.1. Clinicians should offer osimertinib. 1.1.1. Clinicians may offer osimertinib with platinum doublet chemotherapy or amivantamab plus lazertinib Qualifying Statement: Although Recommendation 1.1 addresses many patients in the target population, the guideline manuscript presents additional options that may be reasonable, based on the evidence reviewed. In addition, use of osimertinib in patients previously treated with adjuvant tyrosine kinase inhibitors is not reflected in this guideline. Second-Line & Subsequent Treatment Options Update. 2.2. For patients who have progressive disease on osimertinib or other EGFR TKIs without emergent T790M or other targetable alterations, clinicians may offer platinum-based chemotherapy with or without amivantamab Qualifying Statement: Patients that do not pursue amivantamab plus chemotherapy may also consider chemotherapy plus bevacizumab if they have adenocarcinoma and bevacizumab is deemed safe. 2.2.2. For patients who have progressive disease on EGFR TKI, anti-PD-(L)1 agents with or without platinum chemotherapy are not recommended
November 12, 2024 at 9:21 PM
brittanyeharvey.bsky.social
Dr. Hedy Kindler discussed these latest changes to evidence-based recommendations on the treatment of pleural mesothelioma with me on a new episode of the #ASCOguidelines podcast #medsky #oncsky podcasts.apple.com/us/podcast/t...
Treatment of Pleural Mesothelioma Update
Podcast Episode · ASCO Guidelines · 01/08/2025 · 11m
podcasts.apple.com
January 8, 2025 at 9:17 PM
brittanyeharvey.bsky.social
Our latest guideline update on sentinel lymph node biopsy in patients with early-stage breast cancer treated with initial surgery @ascocancer.bsky.social #ASCOguidelines #MedSky #OncSky
ASCO Guidelines Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Guideline Update This guideline updates recommendations on the use of SLNB in patients with early-stage breast cancer treated with initial surgery, and includes the following topics: When SLNB can be omitted When ALND is indicated Radiation and systemic treatment decisions after SLNB omission Role of SLNB in special circumstances Park et al J Clin Oncol 2025 asco.org/breast-cancer-guidelines
April 11, 2025 at 12:31 PM
brittanyeharvey.bsky.social
Latest guideline from @ascocancer.bsky.social on germline & somatic genomic testing for metastatic prostate cancer published today #ASCOguidelines #medsky #oncsky ascopubs.org/doi/full/10....
ASCO Guidelines Germline & Somatic Genomic Testing for Metastatic Prostate Cancer Includes algorithm on flow of genomic/somatic testing and genetic testing for all patients with metastatic prostate cancer. Yu et al J Clin Oncol 2025 asco.org/genitourinary-cancer-guidelines
January 9, 2025 at 9:36 PM
brittanyeharvey.bsky.social
New update to the neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer from @ascocancer.bsky.social covering many evidence-based recommendations on the use of NACT across ten clinical questions #ASCOguidelines #medsky #oncsky ascopubs.org/doi/full/10....
ASCO Guidelines Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline update including recommendations on: Initial Assessment Primary Cytoreductive Surgery Neoadjuvant Chemotherapy Confirmation of Diagnosis Preferred Chemotherapy Regimens Timing of Interval Cytoreductive Surgery Role of Hyperthermic Intraperitoneal Chemotherapy Recommended Number of Chemotherapy Cycles Maintenance Therapy Options for Patients with Progressive Disease on Neoadjuvant Chemotherapy Gaillard et al J Clin Oncol 2025 asco.org/gynecologic-cancer-guidelines
January 23, 2025 at 3:00 PM
brittanyeharvey.bsky.social
Rapid recommendation update from @ascocancer.bsky.social & @neuroonc.bsky.social on therapy for diffuse astrocytic & oligodendroglial tumors in adults #ASCOguidelines #oncsky #medsky

ascopubs.org/doi/full/10....
Visual Abstract for ASCO-SNO Guideline Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults Rapid Guideline Update Oligodendroglioma, IDH-mutant, 1p19q co-deleted, CNS WHO grade 2 Options Include: - RT + PCV - When toxicity is a concern, RT + temozolimide - For some people with favorable prognostic factors or concerns about toxicity, deferred RT + chemotherapy until radiographic or symptomatic progression - After 1+ surgeries, when RT + chemotherapy has been or can be deferred, vorasidenib may be offered Astrocytoma, IDH-mutant, 1p19q non-codeleted, CNS WHO grade 2 Options include: - RT + adjuvant chemotherapy (temozolimide or PCV) - For some people with favorable prognostic factors or concerns about short- and long-term toxicity, deferred RT + chemotherapy until radiographic or symptomatic progression - After 1+ surgeries, when RT + chemotherapy has been or can be deferred, vorasidenib may be offered Mohile et al J Clin Oncol 2025 asco.org/neurooncology-guidelines
April 30, 2025 at 1:47 PM
brittanyeharvey.bsky.social
Dr. Irene Su from @ucsdhealthsci.bsky.social & Dr. Alison Loren from @pennmedicine.bsky.social joined me on the #ASCOguidelines podcast to discuss this fertility preservation guideline update, including the new recommendations, current challenges & ongoing research podcasts.apple.com/us/podcast/f...
Fertility Preservation in People with Cancer Guideline Update
Podcast Episode · ASCO Guidelines · 03/19/2025 · 32m
podcasts.apple.com
March 19, 2025 at 8:33 PM
brittanyeharvey.bsky.social
Updates just released for two companion living @ascocancer.bsky.social guidelines on stage IV NSCLC

Updated recommendations for stage IV NSCLC without driver alterations include a new second-line option for patients with good PS & HER2 overexpression #ASCOguidelines
ascopubs.org/doi/10.1200/...
Visual abstract describing updated recommendations in the 2024.3 version of the therapy for stage IV NSCLC without driver alterations guideline
February 27, 2025 at 9:32 PM
brittanyeharvey.bsky.social
Dr. @vanmorrismd.bsky.social discussed the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma with me on the #ASCOguidelines podcast - highlighting key recs, considerations for special populations & future research areas podcasts.apple.com/us/podcast/s...
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma Guideline
Podcast Episode · ASCO Guidelines · 12/16/2024 · 16m
podcasts.apple.com
December 17, 2024 at 3:17 PM
brittanyeharvey.bsky.social
On the @ascocancer.bsky.social guidelines podcast, Dr. Nimish Mohile & Dr. Jaishri Blakeley review the evidence from the INDIGO trial that prompted this guideline update, and how to incorporate the use of vorasidenib into clinical practice #ASCOguidelines #oncsky podcasts.apple.com/us/podcast/t...
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Rapid Update
Podcast Episode · ASCO Guidelines · 04/29/2025 · 9m
podcasts.apple.com
April 30, 2025 at 1:47 PM
brittanyeharvey.bsky.social
I spoke with co-chair Dr. Lyudmila Bazhenova from UCSD about this latest stage IV NSCLC living guideline update on the #ASCOguidelines podcast, discussing evidence from MARIPOSA, MARIPOSA-2, CheckMate 722 & KEYNOTE-789 that informed these updated recommendations podcasts.apple.com/us/podcast/a...
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.2
Podcast Episode · ASCO Guidelines · 11/12/2024 · 10m
podcasts.apple.com
November 12, 2024 at 9:21 PM
brittanyeharvey.bsky.social
New evidence-based @ascocancer.bsky.social guideline out on TORS in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma #ASCOguidelines
ascopubs.org/doi/full/10....
ASCO Guidelines Transoral Robotic Surgery in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma Guideline update including recommendations on: Evaluation & Workup of Patients with OPC for TORS Goal of TORS Patient Selection Adjuvant Therapy Role of TORS in HPV-negative OPC Use of TORS in Salvage or Recurrent Setting Holsinger et al J Clin Oncol 2025 asco.org/head-neck-cancer-guidelines
February 11, 2025 at 9:31 PM
brittanyeharvey.bsky.social
Dr. Lyudmila Bazhenova from @ucsdhealthsci.bsky.social provides an overview of the stage IV NSCLC without driver alterations guideline update on the #ASCOguidelines podcast, including evidence reviewed and what this update means for clinicians & patients podcasts.apple.com/us/podcast/t...
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2024.3 Part 1
Podcast Episode · ASCO Guidelines · 02/27/2025 · 11m
podcasts.apple.com
February 27, 2025 at 9:32 PM
brittanyeharvey.bsky.social
Dr. Chris Holsinger from @stanfordmedicine.bsky.social discusses these new recommendations on TORS for patients with OPC, the importance of multidisciplinary collaboration & shared decision-making between patients & clinicians on the #ASCOguidelines podcast podcasts.apple.com/us/podcast/t...
TORS in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma Guideline
Podcast Episode · ASCO Guidelines · 02/11/2025 · 22m
podcasts.apple.com
February 11, 2025 at 9:31 PM
brittanyeharvey.bsky.social
Dr. Stephanie Gaillard from Johns Hopkins University and Dr. Bill Tew from @mskcancercenter.bsky.social discuss the NACT for ovarian cancer recommendation updates, the evidence underpinning these changes, and the importance of this guideline on the #ASCOguidelines podcast tinyurl.com/52xb6edm
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline Update
Podcast Episode · ASCO Guidelines · 01/22/2025 · 19m
podcasts.apple.com
January 23, 2025 at 3:00 PM
oncoassist.bsky.social
🔷 This comprehensive update incorporates the latest evidence published since the previous guideline, with changes that may have a meaningful impact on clinical practice.

🔗 Read more: bit.ly/ONCOnews04Fe...

#ONCOnews #OncoAlert #OncEd #ASCOGuidelines #LivingGuideline #NSCLC #NonSmallCellLungCancer
February 4, 2026 at 12:30 PM